Amneal CEO: Changes At Teva, Sandoz And Viatris Give Us Room To Grow

Chirag Patel Talks International Expansion And Focus On Complex Generics

Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.

Paper planes red break away from pack
Amneal sees room to grow amid change for the big three firms • Source: Shutterstock

With Teva under new management, Sandoz preparing to be spun off from parent company Novartis and Viatris increasingly focusing on areas outside of the off-patent sector, Amneal co-CEO Chirag Patel sees such industry upheaval as an opportunity for the US generics and biosimilars player.

Speaking at the J.P. Morgan Healthcare Conference in San Francisco, Patel observed that “the changes that are happening in the market are actually favorable to us, such as Sandoz going public by itself (Also see "Sandoz Set To Become Public Company In 2023 As Novartis Confirms Spin-Off" - Generics Bulletin, 25 August, 2022.); Teva having a new leadership (Also see "Five Things Facing Teva’s New CEO Richard Francis" - Generics Bulletin, 24 November, 2022.); and Viatris focusing on other areas

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business